Ardelyx reports Q3 EPS 0c, consensus (7c)

Reports Q3 revenue $110.33M, consensus $100.54M. “This quarter’s results highlight the growth of our business as we advance toward year-end and position Ardelyx (ARDX) for an even stronger performance in 2026,” said Mike Raab, president and chief executive officer of Ardelyx. “IBSRELA continues to outperform, driven by sustained demand from IBS-C patients seeking a differentiated treatment option and by the effectiveness of our targeted commercial execution. Our strategy translated into expanded patient adoption, accelerated revenue growth and increased conviction for the long-term value of this franchise. For XPHOZAH, we are encouraged by the consistent growth, despite the dynamic market environment. The progress we are making underscores the agility and discipline of our team, as well as the strength of our commercial model. Finally, the announcement of RDX10531, our next generation NHE3 inhibitor, underscores our leadership in NHE3 inhibition and represents a pivotal step in building a pipeline of important medicines.”